Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAX-D pramipexole add-on trial in treatment-resistant depression
2019-001023-13Phase 4Unknown
- Sponsor
- University of Oxford
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in treatment-resistant depression (TRD) and major depressive disorder (MDD) comparing Pramipexole add-on with Placebo add-on (2 arms). Primary endpoint: Change in depressive symptoms at 12 weeks. Status: unknown.
02
Drugs
pramipexole
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2019-001023-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001023-13.